Immunomodulatory drug therapy for the disease caused by SARS-CoV-2 infection (COVID-19)

Cover Page


Cite item

Full Text

Abstract

This systematic review focuses on the state-of-the-art pharmacotherapy of immune disorders in the novel coronavirus infection (COVID-19), leading to a cytokine storm and uncontrolled inflammatory response that causes severe tissue damage and multiple organ failure. A lot of theoretical, experimental and clinical data support the need for immunomodulatory (immunosuppressive) therapy for this disease. It should be emphasized that all immunomodulatory drugs for COVID-19 are prescribed off label, and the evidence base of the results of randomized trials is just being accumulated. We review the immunomodulatory therapy for COVID-19 with the following agents: glucocorticoids, hydroxychloroquine and chloro-quine, type 1 interferons, interleukin-6 antagonists (tocilizumab, sarilumab, olokizumab), interleukin-1 p inhibitor canakinumab, tumour necrosis factor inhibitors (infliximab), Janus kinase (JAK) inhibitors (tofacitinib, baricitinib, ruxolitinib), as well as drugs with other mechanisms of action (abatacept, nivolumab, tacrolimus, sirolimus, fingolimod, melphalan, cyclosporine, methotrexate). At the moment, the most reasonable is the use of interleukin-6 receptor inhibitors, intermediate and high dose glucocorticoids, and JAK inhibitors. Based on the latest data from clinical studies, especially the "Solidarity” trial, the use of hydroxychloroquine and chloroquine seems to have insufficient evidence. There are significant pathophysiological overlaps in the development of immunopathology in COVID-19 and in rheumatic diseases, and the strategy of early aggressive immunosuppressive therapy proposed by a number of researchers almost completely coincides with the current strategies for rheumatoid arthritis.

About the authors

D. E. Karateev

Moscow Regional Research and Clinical Institute (MONIKI)

Author for correspondence.
Email: dekar@inbox.ru
ORCID iD: 0000-0002-2352-4080

Dmitry E. Karateev - MD, PhD, Head of Department of Rheumatology; Professor, Chair of Therapy, Postgraduate Training Faculty.

61/2 Shchepkina ul., Moscow, 129110, Tel.: +7 (495) 631 74 16

Россия

E. L. Luchikhina

Moscow Regional Research and Clinical Institute (MONIKI)

Email: eleluch@yandex.ru
ORCID iD: 0000-0002-6519-1106

Elena L. Luchikhina - MD, PhD, Leading Research Fellow, Department of Rheumatology; Associate Professor, Chair of Therapy, Postgraduate Training Faculty.

61/2 Shchepkina ul., Moscow, 129110

Россия

References

  1. Министерство здравоохранения Российской Федерации. Коронавирус - симптомы, признаки, общая информация, ответы на вопросы [Интернет]. Доступно на: https://covid19.rosminzdrav.ru.
  2. Министерство здравоохранения Российской Федерации. Временные методические рекомендации: профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19) [Интернет]. Версия 7 (03.06.2020). Доступно на: https://static-0.rosminzdrav.ru/system/attachments/attaches/000/050/584/original/03062020_MR_COVID-19_v7.pdf.
  3. World Health Organization. Severe acute respiratory syndrome (SARS): report by the Secretariat [Internet]. Available from: https://apps. who.int/iris/handle/10665/20038.
  4. Chafekar A, Fielding BC. MERS-CoV: Understanding the Latest Human Coronavirus Threat. Viruses. 2018;10(2):93. doi: 10.3390/v10020093.
  5. Astuti I, Ysrafil. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): An overview of viral structure and host response. Diabetes Metab Syndr. 2020;14(4):407-12. doi: 10.1016/j.dsx.2020.04.020.
  6. Jamilloux Y, Henry T, Belot A, Viel S, Fauter M, El Jammal T, Walzer T, Francois B, Seve P. Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions. Autoimmun Rev. 2020;19(7):102567. doi: 10.1016/j.autrev.2020.102567.
  7. Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science. 2020;367(6485): 1444-8. doi: 10.1126/science.abb2762.
  8. Lin L, Lu L, Cao W, Li T. Hypothesis for potential pathogenesis of SARS-CoV-2 infection - a review of immune changes in patients with viral pneumonia. Emerg Microbes Infect. 2020;9(1): 727-32. doi: 10.1080/22221751.2020.1746199.
  9. Ferrara JL, Abhyankar S, Gilliland DG. Cytokine storm of graft-versus-host disease: a critical effector role for interleukin-1. Transplant Proc. 1993;25(1 Pt 2):1216-7.
  10. Tisoncik JR, Korth MJ, Simmons CP, Farrar J, Martin TR, Katze MG. Into the eye of the cytokine storm. Microbiol Mol Biol Rev. 2012;76(1): 16-32. doi: 10.1128/MMBR.05015-11.
  11. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ; HLH Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033-4. doi: 10.1016/S0140-6736(20)30628-0.
  12. McGonagle D, Sharif K, O'Regan A, Bridge-wood C. The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease. Autoimmun Rev. 2020;19(6):102537. doi: 10.1016/j.autrev.2020.102537.
  13. Karakike E, Giamarellos-Bourboulis EJ. Macrophage Activation-Like Syndrome: A Distinct Entity Leading to Early Death in Sepsis. Front Immunol. 2019;10:55. doi: 10.3389/fim-mu.2019.00055.
  14. Jamilloux Y, Gerfaud-Valentin M, Marti-non F, Belot A, Henry T, Seve P. Pathogenesis of adult-onset Still's disease: new insights from the juvenile counterpart. Immunol Res. 2015;61(1-2):53-62. doi: 10.1007/s12026-014-8561-9.
  15. Huppert LA, Matthay MA, Ware LB. Pathogenesis of Acute Respiratory Distress Syndrome. Semin Respir Crit Care Med. 2019;40(1):31-9. doi: 10.1055/s-0039-1683996.
  16. Всемирная организация здравоохранения. Европейское региональное бюро. Клиническое ведение тяжелой острой респираторной инфекции: методическое пособие. Версия, адаптированная для борьбы с COVID-19 [Интернет]. 2020. Доступно на: https://apps.who.int/iris/bitstream/han-dle/10665/333080/WHO-2019-nCoV-SA-RI-toolkit-2020.1-rus.pdf?sequence=1&is-Allowed=y.
  17. Всемирная организация здравоохранения. Клиническое ведение случаев COVID-19. Временное руководство [Интернет]. 27.05.2020. Доступно на: https://apps.who.int/iris/bitstream/handle/10665/332196/WHO-2019-nCoV-clinical-2020.5-rus.pdf.
  18. Lamontagne F, Rochwerg B, Lytvyn L, Guyatt GH, M0ller MH, Annane D, Kho ME, Adhikari NKJ, Machado F, Vandvik PO, Do-dek P, Leboeuf R, Briel M, Hashmi M, Camsook-sai J, Shankar-Hari M, Baraki MK, Fugate K, Chua S, Marti C, Cohen D, Botton E, Agorit-sas T, Siemieniuk RAC. Corticosteroid therapy for sepsis: a clinical practice guideline. BMJ. 2018;362:k3284. doi: 10.1136/bmj.k3284.
  19. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, Huang H, Zhang L, Zhou X, Du C, Zhang Y, Song J, Wang S, Chao Y, Yang Z, Xu J, Zhou X, Chen D, Xiong W, Xu L, Zhou F, Jiang J, Bai C, Zheng J, Song Y. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med. 2020;180(7):1 — 11. Epub ahead of print. doi: 10.1001/jamainternmed.2020.0994.
  20. Liu J, Zheng X, Huang Y, Shan H, Huang J. Successful use of methylprednisolone for treating severe COVID-19. J Allergy Clin Immunol. 2020;146(2):325-7. doi: 10.1016/j.jaci.2020.05.021.
  21. Gong Y, Guan L, Jin Z, Chen S, Xiang G, Gao B. Effects of methylprednisolone use on viral genomic nucleic acid negative conversion and CT imaging lesion absorption in COVID-19 patients under 50 years old. J Med Virol. 2020. Epub ahead of print. doi: 10.1002/jmv.26052.
  22. Hu Z, Lv Y, Xu C, Sun W, Chen W, Peng Z, Chen C, Cui X, Jiao D, Cheng C, Chi Y, Wei H, Hu C, Zeng Y, Zhang X, Yi Y. Clinical Use of Short-Course and Low-Dose Corticosteroids in Patients With Non-severe COVID-19 During Pneumonia Progression. Front Public Health. 2020;8:355. doi: 10.3389/fpubh.2020.00355.
  23. Мареев ВЮ, Орлова ЯА, Павликова ЕП, Мацкеплишвили СТ, Краснова ТН, Малахов ПС, Самоходская ЛМ, Мершина ЕА, Синицин ВЕ, Мареев ЮВ, Калинкин АЛ, Беграмбекова ЮЛ, Камалов АА. ПУльс-Терапия стероидными гормоНамИ больных с Коронавирусной пневмонией (COVID-19), системным воспалением и риском венозных тромбозов и тромбоэмболий (исследование ПУТНИК). Кардиология. 2020;60(6):15-29. doi: 10.18087/cardio.2020.6.n1226.
  24. Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, Doudier B, Courjon J, Giordanengo V, Vieira VE, Tissot Dupont H, Honore S, Colson P, Chabriere E, La Scola B, Rolain JM, Brouqui P, Raoult D. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-ran-domized clinical trial. Int J Antimicrob Agents. 2020;56(1):105949. doi: 10.1016/j.ijantimi-cag.2020.105949.
  25. Chiappelli F, Khakshooy A, Greenberg G. CoViD-19 Immunopathology and Immunotherapy. Bioinformation. 2020;16(3):219-22. doi: 10.6026/97320630016219.
  26. Tang W, Cao Z, Han M, Wang Z, Chen J, Sun W, Wu Y, Xiao W, Liu S, Chen E, Chen W, Wang X, Yang J, Lin J, Zhao Q, Yan Y, Xie Z, Li D, Yang Y, Liu L, Qu J, Ning G, Shi G, Xie Q. Hydroxychloroquine in patients mainly with mild to moderate COVID-19: an open-label, randomized, controlled trial. medRxiv. 2020 May 7. Preprint. doi: 10.1101/2020.04.10.20060558.
  27. Gao J, Tian Z, Yang X. Breakthrough: Chloro-quine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020;14(1): 72-3. doi: 10.5582/bst.2020.01047.
  28. Mahevas M, Tran VT, Roumier M, Chabrol A, Paule R, Guillaud C, Gallien S, Lepeule R, Szweb-el TA, Lescure X, Schlemmer F, Matignon M, Khellaf M, Crickx E, Terrier B, Morbieu C, Legendre P, Dang J, Schoindre Y, Pawlotski JM, Michel M, Perrodeau E, Carlier N, Roche N, De Lastours V, Mouthon L, Audureau E, Rav-aud P, Godeau B, Costedoat N. No evidence of clinical efficacy of hydroxychloroquine in patients hospitalized for COVID-19 infection with oxygen requirement: results of a study using routinely collected data to emulate a target trial. medRxiv. 2020 Apr 14. Preprint. doi: 10.1101/2020.04.10.20060699.
  29. Molina JM, Delaugerre C, Le Goff J, Mela-Li-ma B, Ponscarme D, Goldwirt L, de Castro N. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. Med Mal Infect. 2020;50(4):384. doi: 10.1016/j.med-mal.2020.03.006.
  30. Chen J, Liu D, Liu L, Liu P, Xu Q, Xia L, Ling Y, Huang D, Song S, Zhang D, Qian Z, Li T, Shen Y, Lu H. [A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19]. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020;49(2):215-9. Chinese. doi: 10.3785/j.issn.1008-9292.2020.03.03.
  31. Borba MGS, de Almeida Val F, Sousa Sam-paio V, Araujo Alexandre MA, Cardoso Melo G, Brito M, Gomes Mourao MP, Sousa JDB, Baia-da-Silva DC, Farias Guerra MV, Abrahao Hajjar L, Costa Pinto R, Silva Balieiro AA, Gomes Naveca F, Simao Xavier M, Salomao A, Machado Siqueira A, Schwarzbolt A, Rosa Cro-da JH, Lacerda Nogueira M, Sierra Romero GA, Bassat Q, Jesus Fontes C, Albuquerque BC, Daniel-Ribeiro CT, Monteiro WM, Guimaraes Lacerda MV; CloroCovid-19 Team. Chloro-quine diphosphate in two different dosages as adjunctive therapy of hospitalized patients with severe respiratory syndrome in the context of coronavirus (SARS-CoV-2) infection: Preliminary safety results of a randomized, double-blinded, phase IIb clinical trial (Cloro-Covid-19 Study). medRxiv. 2020 Apr 16. Preprint. doi: 10.1101/2020.04.07.20056424.
  32. Thoguluva Chandrasekar V, Venkatesalu B, Patel HK, Spadaccini M, Manteuffel J, Ramesh M. Systematic review and meta-analysis of effectiveness of treatment options against SARS-CoV-2 infection. J Med Virol. 2020. Epub ahead of print. doi: 10.1002/jmv.26302.
  33. Всемирная организация здравоохранения. ВОЗ прекращает изыскания в группах лечения COVID-19 гидроксихлорохином и комбинацией лопинавира и ритонавира: выпуск новостей [Интернет]. 04.07.2020. Доступно на: https://www.who.int/ru/news-room/de-tail/04-07-2020-who-discontinues-hydroxy-chloroquine-and-lopinavir-ritonavir-treat-ment-arms-for-covid-19.
  34. Zhou Q, Wei XS, Xiang X, Wang X, Wang ZH, Chen V, Shannon CP, Tebbutt SJ, Kollmann TR, Fish EN. Interferon-a2b treatment for COVID-19. medRxiv. 2020 Apr 10. Preprint. doi: 10.1101/2020.04.06.20042580.
  35. Meng Z, Wang T, Li C, Chen X, Li L, Qin X, Li H, Luo J. An experimental trial of recombinant human interferon alpha nasal drops to prevent coronavirus disease 2019 in medical staff in an epidemic area. medRxiv. 2020 May 7. Preprint. doi: 10.1101/2020.04.11.20061473.
  36. Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizum-ab treatment in COVID-19: A single center experience. J Med Virol. 2020;92(7):814-8. doi: 10.1002/jmv.25801.
  37. Xu X, Han M, Li T, Sun W, Wang D, Fu B, Zhou Y, Zheng X, Yang Y, Li X, Zhang X, Pan A, Wei H. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci USA. 2020;117(20):10970-5. doi: 10.1073/pnas.2005615117.
  38. Morena V, Milazzo L, Oreni L, Bestetti G, Fos-sali T, Bassoli C, Torre A, Cossu MV, Minari C, Ballone E, Perotti A, Mileto D, Niero F, Merli S, Foschi A, Vimercati S, Rizzardini G, Sollima S, Bradanini L, Galimberti L, Colombo R, Micheli V, Negri C, Ridolfo AL, Meroni L, Galli M, Antino-ri S, Corbellino M. Off-label use of tocilizumab for the treatment of SARS-CoV-2 pneumonia in Milan, Italy. Eur J Intern Med. 2020;76:36-42. doi: 10.1016/j.ejim.2020.05.011.
  39. Maeda T, Obata R, Rizk DO D, Kuno T. The Association of Interleukin-6 value, Interleukin inhibitors and Outcomes of Patients with COVID-19 in New York City. J Med Virol. 2020. Epub ahead of print. doi: 10.1002/jmv.26365.
  40. Canziani LM, Trovati S, Brunetta E, Testa A, De Santis M, Bombardieri E, Guidelli G, Albano G, Folci M, Squadroni M, Beretta GD, Ciccarelli M, Castoldi M, Lleo A, Aghemo A, Vernile L, Males-ci A, Omodei P, Angelini C, Badalamenti S, Cecconi M, Cremonesi A, Selmi C; Humanitas and Gavazzeni / Castelli COVID-19 Task Forces. Interleukin-6 receptor blocking with intravenous tocilizumab in COVID-19 severe acute respiratory distress syndrome: A retrospective case-control survival analysis of 128 patients. J Autoimmun. 2020. Epub ahead of print. doi: 10.1016/j.jaut.2020.102511.
  41. Ramiro S, Mostard RLM, Magro-Checa C, van Dongen CMP, Dormans T, Buijs J, Gronen-schild M, de Kruif MD, van Haren EHJ, van Kraaij T, Leers MPG, Peeters R, Wong DR, Landewe RBM. Historically controlled comparison of glucocorticoids with or without tocili-zumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study. Ann Rheum Dis. 2020;79(9):1143-51. doi: 10.1136/ann-rheumdis-2020-218479.
  42. Benucci M, Giannasi G, Cecchini P, Gobbi FL, Damiani A, Grossi V, Infantino M, Manfredi M. COVID-19 pneumonia treated with Sarilum-ab: A clinical series of eight patients. J Med Virol. 2020. Epub ahead of print. doi: 10.1002/jmv.26062.
  43. Della-Torre E, Campochiaro C, Cavalli G, De Luca G, Napolitano A, La Marca S, Boffini N, Da Prat V, Di Terlizzi G, Lanzillotta M, Rovere Quer-ini P, Ruggeri A, Landoni G, Tresoldi M, Ciceri F, Zangrillo A, De Cobelli F, Dagna L; SARI-RAF Study Group; SARI-RAF Study Group members. Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study. Ann Rheum Dis. 2020. Epub ahead of print. doi: 10.1136/annrheumdis-2020-218122.
  44. Stallmach A, Kortgen A, Gonnert F, Coldew-ey SM, Reuken P, Bauer M. Infliximab against severe COVID-19-induced cytokine storm syndrome with organ failure - a cautionary case series. Crit Care. 2020;24(1):444. doi: 10.1186/s13054-020-03158-0.
  45. Cantini F, Niccoli L, Matarrese D, Nicastri E, Stobbione P, Goletti D. Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact. J Infect. 2020;81(2):318-56. doi: 10.1016/j.jinf.2020.04.017.
  46. Titanji BK, Farley MM, Mehta A, Connor-Schul-er R, Moanna A, Cribbs SK, O'Shea J, DeSilva K, Chan B, Edwards A, Gavegnano C, Schinazi RF, Marconi VC. Use of Baricitinib in Patients with Moderate and Severe COVID-19. Clin Infect Dis. 2020. Epub ahead of print. doi: 10.1093/cid/ciaa879.
  47. Cantini F, Niccoli L, Nannini C, Matarrese D, Natale MED, Lotti P, Aquilini D, Landini G, Cimolato B, Pietro MAD, Trezzi M, Stobbi-one P, Frausini G, Navarra A, Nicastri E, Sotgiu G, Goletti D. Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study. J Infect. 2020. Epub ahead of print. doi: 10.1016/j.jinf.2020.06.052.
  48. La Rosee F, Bremer HC, Gehrke I, Kehr A, Hoch-haus A, Birndt S, Fellhauer M, Henkes M, Kum-le B, Russo SG, La Rosee P. The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation. Leukemia. 2020;34(7):1805-15. doi: 10.1038/s41375-020-0891-0.
  49. Cao Y, Wei J, Zou L, Jiang T, Wang G, Chen L, Huang L, Meng F, Huang L, Wang N, Zhou X, Luo H, Mao Z, Chen X, Xie J, Liu J, Cheng H, Zhao J, Huang G, Wang W, Zhou J. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial. J Allergy Clin Immunol. 2020;146(1):137-46.e3. doi: 10.1016/j.jaci.2020.05.019.
  50. Tsang K, Seto WH. Severe acute respiratory syndrome: scientific and anecdotal evidence for drug treatment. Curr Opin Investig Drugs. 2004;5(2):179-85.
  51. Carter SJ, Tattersall RS, Ramanan AV. Macrophage activation syndrome in adults: recent advances in pathophysiology, diagnosis and treatment. Rheumatology (Oxford). 2019;58(1): 5-17. doi: 10.1093/rheumatology/key006.
  52. Ho JC, Ooi GC, Mok TY, Chan JW, Hung I, Lam B, Wong PC, Li PC, Ho PL, Lam WK, Ng CK, Ip MS, Lai KN, Chan-Yeung M, Tsang KW. High-dose pulse versus nonpulse corticosteroid regimens in severe acute respiratory syndrome. Am J Re-spir Crit Care Med. 2003;168(12):1449-56. doi: 10.1164/rccm.200306-766OC.
  53. Yam LY, Lau AC, Lai FY, Shung E, Chan J, Wong V; Hong Kong Hospital Authority SARS Collaborative Group (HASCOG). Corticosteroid treatment of severe acute respiratory syndrome in Hong Kong. J Infect. 2007;54(1):28-39. doi: 10.1016/j.jinf.2006.01.005.
  54. Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. PLoS Med. 2006;3(9):e343. doi: 10.1371/journal.pmed.0030343.
  55. Lamontagne F, Briel M, Guyatt GH, Cook DJ, Bhatnagar N, Meade M. Corticosteroid therapy for acute lung injury, acute respiratory distress syndrome, and severe pneumonia: a meta-analysis of randomized controlled trials. J Crit Care. 2010;25(3):420-35. doi: 10.1016/j.jcrc.2009.08.009.
  56. Ashbaugh DG, Bigelow DB, Petty TL, Levine BE. Acute respiratory distress in adults. Lancet. 1967;2(7511 ):319-23. doi: 10.1016/s0140-6736(67)90168-7.
  57. Lewis SR, Pritchard MW, Thomas CM, Smith AF. Pharmacological agents for adults with acute respiratory distress syndrome. Cochrane Database Syst Rev. 2019;7(7):CD004477. doi: 10.1002/14651858.CD004477.pub3.
  58. Villar J, Ferrando C, Martinez D, Am-bros A, Munoz T, Soler JA, Aguilar G, Alba F, Gonzalez-Higueras E, Conesa LA, Martin-Rodri-guez C, Diaz-Dominguez FJ, Serna-Grande P, Rivas R, Ferreres J, Belda J, Capilla L, Tallet A, Anon JM, Fernandez RL, Gonzalez-Martin JM; dexamethasone in ARDS network. Dexameth-asone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. Lancet Respir Med. 2020;8(3): 267-76. doi: 10.1016/S2213-2600(19)30417-5.
  59. Claesson J, Freundlich M, Gunnarsson I, Laake JH, Moller MH, Vandvik PO, Varpula T, Aasmundstad TA. Scandinavian clinical practice guideline on fluid and drug therapy in adults with acute respiratory distress syndrome. Acta Anaesthesiol Scand. 2016;60(6): 697-709. doi: 10.1111/aas.12713.
  60. Fan E, Brodie D, Slutsky AS. Acute Respiratory Distress Syndrome: Advances in Diagnosis and Treatment. JAMA. 2018;319(7):698-710. doi: 10.1001/jama.2017.21907.
  61. ООО «Федерация анестезиологов-реани-матологов». Диагностика и интенсивная терапия острого респираторного дистресс-синдрома: рекомендации [Интернет]. 30.03.2020. Доступно на: http://far.org.ru/ recomendation#.
  62. Li H, Chen C, Hu F, Wang J, Zhao Q, Gale RP, Liang Y. Impact of corticosteroid therapy on outcomes of persons with SARS-CoV-2, SARS-CoV, or MERS-CoV infection: a systematic review and meta-analysis. Leukemia. 2020;34(6): 1503-11. doi: 10.1038/S41375-020-0848-3.
  63. Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, Seidah NG, Nichol ST. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2005;2:69. doi: 10.1186/1743-422X-2-69.
  64. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269-71. doi: 10.1038/s41422-020-0282-0.
  65. Salvi R, Patankar P. Emerging pharmacotherapies for COVID-19. Biomed Pharmaco-ther. 2020;128:110267. doi: 10.1016/j.bio-pha.2020.110267.
  66. Sallard E, Lescure FX, Yazdanpanah Y, Mentre F, Peiffer-Smadja N. Type 1 interferons as a potential treatment against COVID-19. Antiviral Res. 2020;178:104791. doi: 10.1016/j.antivi-ral.2020.104791.
  67. Sheahan TP, Sims AC, Leist SR, Schafer A, Won J, Brown AJ, Montgomery SA, Hogg A, Babusis D, Clarke MO, Spahn JE, Bauer L, Sellers S, Porter D, Feng JY, Cihlar T, Jordan R, Denison MR, Baric RS. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020;11(1):222. doi: 10.1038/s41467-019-13940-6.
  68. Omrani AS, Saad MM, Baig K, Bahloul A, Ab-dul-Matin M, Alaidaroos AY, Almakhlafi GA, Al-barrak MM, Memish ZA, Albarrak AM. Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study. Lancet Infect Dis. 2014;14(11):1090-5. doi: 10.1016/S1473-3099(14)70920-X.
  69. Arabi YM, Shalhoub S, Mandourah Y, Al-Ha-meed F, Al-Omari A, Al Qasim E, Jose J, Alradd-adi B, Almotairi A, Al Khatib K, Abdulmomen A, Qushmaq I, Sindi AA, Mady A, Solaiman O, Al-Raddadi R, Maghrabi K, Ragab A, Al Mekhla-fi GA, Balkhy HH, Al Harthy A, Kharaba A, Gram-ish JA, Al-Aithan AM, Al-Dawood A, Merson L, Hayden FG, Fowler R. Ribavirin and Interferon Therapy for Critically Ill Patients With Middle East Respiratory Syndrome: A Multicenter Observational Study. Clin Infect Dis. 2020;70(9): 1837-44. doi: 10.1093/cid/ciz544.
  70. Solis-Garcia Del Pozo J, Galindo MF, Nava E, Jordan J. A systematic review on the efficacy and safety of IL-6 modulatory drugs in the treatment of COVID-19 patients. Eur Rev Med Pharmacol Sci. 2020;24(13):7475-84. doi: 10.26355/eurrev_202007_21916.
  71. Mazurov V, Zotkin E, Ilivanova E, Kropoti-na T, Plaksina T, Nesmeyanova O, Soroka N,
  72. Kundzer A, Lutskii A, Dokukina E, Chernyaeva E, Ivanov R. Short-Term Efficacy Of BCD-089, Novel Monoclonal Anti-IL-6 Receptor Antibody, In Combination With Methotrexate In Patients With Rheumatoid Arthritis: 12-Week Results Of Phase 2 Aurora Study. FRI0108 Conference Paper. Ann Rheum Dis. 78(Suppl 2):721. doi: 10.1136/annrheumdis-2019-eular.7220.
  73. Papa R, Natoli V, Caorsi R, Minoia F, Gattorno M, Ravelli A. Successful treatment of refractory hyperferritinemic syndromes with canakinum-ab: a report of two cases. Pediatr Rheumatol Online J. 2020;18(1):56. doi: 10.1186/s12969020-00450-9.
  74. Grom AA, Ilowite NT, Pascual V, Brunner HI, Martini A, Lovell D, Ruperto N; Paediatric Rheumatology International Trials Organisation and the Pediatric Rheumatology Collaborative Study Group, Leon K, Lheritier K, Abrams K. Rate and Clinical Presentation of Macrophage Activation Syndrome in Patients With Systemic Juvenile Idiopathic Arthritis Treated With Canakinumab. Arthritis Rheumatol. 2016;68(1): 218-28. doi: 10.1002/art.39407.
  75. Franzetti M, Pozzetti U, Carugati M, Pandolfo A, Molteni C, Faccioli P, Castaldo G, Longoni E, Ormas V, Iemoli E, Piconi S. Interleukin-1 receptor antagonist anakinra in association with remdesivir in severe COVID-19: A case report. Int J Infect Dis. 2020;97:215-8. doi: 10.1016/j.ijid.2020.05.050.
  76. Salvarani C, Bajocchi G, Mancuso P, Galli E, Muratore F, Boiardi L, Catanoso M, Pipitone N, Cassone G, Girolimetto N, Croci S, Cimino L, Gradellini F, Beltrami M, Di Lernia V, Dol-ci G, Massari M, Marata AM, Costantini M, Giorgi Rossi P. Susceptibility and severity of COVID-19 in patients treated with bDMARDS and tsDMARDs: a population-based study. Ann Rheum Dis. 2020;79(7):986-8. doi: 10.1136/an-nrheumdis-2020-217903.
  77. Bezzio C, Manes G, Bini F, Pellegrini L, Saibeni S. Infliximab for severe ulcerative colitis and subsequent SARS-CoV-2 pneumonia: a stone for two birds. Gut. 2020. Epub ahead of print. doi: 10.1136/gutjnl-2020-321760.
  78. Tursi A, Angarano G, Monno L, Saracino A, Si-gnorile F, Ricciardi A, Papa A. COVID-19 infection in Crohn's disease under treatment with adalimumab. Gut. 2020;69(7):1364-5. doi: 10.1136/gutjnl-2020-321240.
  79. Valenti M, Facheris P, Pavia G, Gargiulo L, Borroni RG, Costanzo A, Narcisi A. Non-complicated evolution of COVID-19 infection in a patient with psoriasis and psoriatic arthritis during treatment with adalimumab. Dermatol Ther. 2020. Epub ahead of print. doi: 10.1111/dth.13708.
  80. Favalli EG, Biggioggero M, Maioli G, Caporali R. Baricitinib for COVID-19: a suitable treatment? Lancet Infect Dis. 2020. Epub ahead of print. doi: 10.1016/S1473-3099(20)30262-0.
  81. Convertino I, Tuccori M, Ferraro S, Valdiserra G, Cappello E, Focosi D, Blandizzi C. Exploring pharmacological approaches for managing cytokine storm associated with pneumonia and acute respiratory distress syndrome in COVID-19 patients. Crit Care. 2020;24(1):331. doi: 10.1186/s13054-020-03020-3.
  82. Jacobs J, Clark-Snustad K, Lee S. Case Report of a SARS-CoV-2 Infection in a Patient With Ulcerative Colitis on Tofacitinib. Inflamm Bowel Dis. 2020;26(7):e64. doi: 10.1093/ibd/izaa093.
  83. Cingolani A, Tummolo AM, Montemurro G, Gremese E, Larosa L, Cipriani MC, Pasciuto G, Liperoti R, Murri R, Pirronti T, Cauda R, Fanto-ni M; for COVID 2 Columbus Working Group. Baricitinib as rescue therapy in a patient with COVID-19 with no complete response to sari-lumab. Infection. 2020. Epub ahead of print. doi: 10.1007/s15010-020-01476-7.
  84. Koschmieder S, Jost E, Cornelissen C, Muller T, Schulze-Hagen M, Bickenbach J, Marx G, Kleines M, Marx N, Brummendorf TH, Dre-her M. Favorable COVID-19 course despite significant comorbidities in a ruxolitinib-treated patient with primary myelofibrosis. Eur J Haematol. 2020. Epub ahead of print. doi: 10.1111/ejh.13480.
  85. Innes AJ, Cook LB, Marks S, Bataillard E, Cros-sette-Thambiah C, Sivasubramaniam G, Ap-perley J, Milojkovic D. Ruxolitinib for tocili-zumab-refractory severe COVID-19 infection. Br J Haematol. 2020. Epub ahead of print. doi: 10.1111/bjh.16979.
  86. Yekeduz E, Dursun B, Aydin G10.1177/1078155220924084.
  87. Bonomi L, Ghilardi L, Arnoldi E, Tondini CA, Bettini AC. A Rapid Fatal Evolution of Corona-virus Disease-19 in a Patient With Advanced Lung Cancer With a Long-Time Response to Nivolumab. J Thorac Oncol. 2020;15(6):e83-5. doi: 10.1016/j.jtho.2020.03.021.
  88. Artigas C, Lemort M, Mestrez F, Gil T, Flamen P. COVID-19 Pneumonia Mimicking Immunotherapy-Induced Pneumonitis on 18F-FDG PET/CT in a Patient Under Treatment With Nivolumab. Clin Nucl Med. 2020;45(8):e381-2. doi: 10.1097/RLU.0000000000003152.
  89. Di Lernia V, Goldust M, Feliciani C. Covid-19 infection in psoriasis patients treated with cyclosporin. Dermatol Ther. 2020. Epub ahead of print. doi: 10.1111/dth.13739.
  90. Sanchez-Pernaute O, Romero-Bueno FI, Sel-va-O'Callaghan A. Why Choose Cyclosporin A as First-line Therapy in COVID-19 Pneumonia. Reumatol Clin. 2020. Epub ahead of print. doi: 10.1016/j.reuma.2020.03.001.
  91. Safavi F, Nath A. Silencing of immune activation with methotrexate in patients with COVID-19. J Neurol Sci. 2020;415:116942. doi: 10.1016/j.jns.2020.116942.
  92. Frohman EM, Villemarette-Pittman NR, Cruz RA, Longmuir R, Rowe V, Rowe ES, Var-key TC, Steinman L, Zamvil SS, Frohman TC. Part II. High-dose methotrexate with leucov-orin rescue for severe COVID-19: An immune stabilization strategy for SARS-CoV-2 induced 'PANIC' attack. J Neurol Sci. 2020;415:116935. doi: 10.1016/j.jns.2020.116935.
  93. Seif F, Pornour M, Mansouri D. Combination of JAKinibs with Methotrexate or Anti-Cytokine Biologics in Patients with Severe COVID-19. Int Arch Allergy Immunol. 2020;181(8):648-9. doi: 10.1159/000509198.
  94. Omarjee L, Janin A, Perrot F, Laviolle B, Meil-hac O, Mahe G. Targeting T-cell senescence and cytokine storm with rapamycin to prevent severe progression in COVID-19. Clin Immunol. 2020;216:108464. doi: 10.1016/j.clim.2020.108464.
  95. Hon KL, Leung KKY, Leung AK, Qian SY, Chan VP, Ip P, Wong IC. Coronavirus disease 2019 (COVID-19): latest developments in potential treatments. Drugs Context. 2020;9:2020-4-15. doi: 10.7573/dic.2020-4-15.
  96. Saxena A. Drug targets for COVID-19 therapeutics: Ongoing global efforts. J Biosci. 2020;45(1):87. doi: 10.1007/s12038-020-00067-w.
  97. Catanzaro M, Fagiani F, Racchi M, Corsini E, Gov-oni S, Lanni C. Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2. Signal Transduct Target Ther. 2020;5(1):84. doi: 10.1038/s41392-020-0191-1.
  98. Каратеев ДЕ, Лучихина ЕЛ. Современные принципы ведения больных с ревматоидным артритом. Медицинский товет. 2017;(17):92-100. doi: 10.21518/2079-701X-2017-17-92-100.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2020 Karateev D.E., Luchikhina E.L.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies